Member Info for parkez

ok heres a wild thought,
Could this be the source of our funding?
"In September 2019 we also launched a non-oriented version of the DermaPure product specifically for the urogynaecology market. Initial feedback from surgeons has been very encouraging. It is important to note that until recently this market was served by synthetic mesh which has now been largely withdrawn from the market, and where the Company expects to realise significant commercial opportunities."
SIGNIFICANT commercial opportunities?
We know their are a vast number of operations carried out yearly utilising the synthetic mesh...a new alternative is Dermapure,tried and tested with excellent results. Meeting demand is maybe the problem for Dermapure to become the new solution.
We know from the Sept 2019 interview that TRX have been approached by 2 companies under NDAs to use their products, i thought originally this would be away from the USA. but maybe not, could we have 2 USA pharmas about to licence and produce Dermapure under their own brand paying royalties, upfront licence fees being the new funding?
Just a thought.

See thats an opinion that a placing is coming...no evidence to support it. Is he saying that because he wants to scare people into selling and deter people from buying or does he really believe and its a genuine opinion?
Do your own research and then YOU decide!

Cant really see what their was to panic about,,,the MMs took the opportunity to try and panic..seems they managed to put the jitters into a few.

Hmm the 7.44am trade?
Sell...before opening, MMs trade to put doubt in minds?

up today or down today....i for one am not bothered.

They have cash available until end of April, was previously end of March.They have taken measures to increase this by one month through the reduction of 18 staff...yet are looking at increasing production with a third shift...
What departments/roles make up these 18 staff? production?
The funding issue is confusing...seems complicated and therefore confusing to us Pis ...if they had a placing in mind surely it would be simper to have just done it by now? Not as if they would have difficulty getting one away...
NO,,,other finance arrangements forthcoming.
Its that word again recapitalisation!!

"It is important to note that until recently this market was served by synthetic mesh which has now been largely withdrawn from the market, and where the Company expects to realise significant commercial opportunities."

Massive market, TRX product Dermapure showing good growth....as its reputation and reliability increases so will the sales...no real alternative available. Massive market...TRX and its potential licencees will monopolise imo.

I get this vision of women chatting at work,at their church meetings,at their mothers chat groups and the main topic is dermapure...they will be going.to their specialist to DEMAND DERMAPURE!!
The future is indeed bright.

when you realise the depth of this market,understand the value of our product,you then understand why Tissue Regenix is being approached by other companies to Licence their ip...

"A woman’s lifetime risk of surgery for pelvic organ prolapse (POP) is 12-19% with over 300?000 prolapse surgeries performed annually in the US alone"

https://www.bmj.com/content/354/bmj.i3853

Consensus of opinion is TR-1 notification that Woodford/Link are out.
Trading update and new products to follow...
Opinions only...Dyor start with the TR1s and woodford and grasp why we are at such a give away price....Then look at what we have to offer clinicians.

As the saying goes "you can lead a horse to water but you cant make it drink"...Bunsen has led you here...up to you if you decide to drink or not. I dont really care one way or another...i,m in and happy to be in.
GL on your decision.

7.7billion world population. 49% women, 50% of those women over 30. 8to11% suffer pelvic organ collapse.
That's a very huge market.
Good find and post Boom.

Its not the word funding..its the word placing thats scares investors...apparently their are those that cannot tell the difference.

Good post Chester,
sort of puts things into perspective . And thats why i am waiting eagerly for the first licence agreement to arrive...validates the ip.
At the moment we appear to have products better than whats currently available...a licensing agreement with a couple of the big pharmaceuticals not only confirms this it accelerates the pathway to profit.
Tells the market what we have is better than the rest...2020 will hopefully see this confirmed..imo. i say hopefully because these agreements can take ages to come to fruition ..the licencee will want an instant roi and get all the production, distribution deals sorted before signing.

https://www.genengnews.com/topics/translational-medicine/oxeco-to-purchase-tissue-regenix-in-12m-share-based-reverse-takeover/

"The acquisition deal is classified under the London Stock Exchange’s AIM rules as a reverse takeover. The enlarged group will retain the Tissue Regenix name and seek a listing on AIM."

Since the admission onto AIM in 2010 whats the highest market cap been? have read it was at one point £200m....is this true ,has it been higher?

Another very interesting read...very interesting and very detailed, old so MOST will have seen it but a must if new here.
https://www.trinitydelta.org/research-notes/creating-the-right-conditions-for-future-growth/

Cant read this too many times...
https://www.proactiveinvestors.co.uk/companies/news/53891/tissue-regenixs-takeover-value-may-eventually-top-us1bn-suggests-broker-63919.html